Filing Flows › Integrated Biopharma (INBP) › Q3 FY25
Integrated Biopharma (INBP) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed May 14, 2025
Integrated Biopharma (INBP) reported revenue of $13.9M for the third quarter fiscal 2025 (Q3 FY25), +6% from a year earlier and +11% from the quarter before. Operating margin was 5.3%, net earnings $611K (4.4% of revenue).
Integrated Biopharma, Q3 FY25: revenue $13.9M (+6% year over year), operating margin 5.3%, net earnings $611K, operating cash flow $616K. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.9M | +11% | +6% |
| Gross profit | $1.6M | +32% | +24% |
| Operating profit | $739K | +266% | +108% |
| Net earnings | $611K | +427% | +114% |
| Operating cash flow | $616K | +206% | -63% |
| Free cash flow | $500K | +191% | -61% |
What changed
Revenue was $13.9M in Q3 FY25, up 6% year over year and up 11% from the previous quarter. Contract Manufacturing was the largest line at 97% of revenue. Contract Manufacturing added $709K year over year (up 6%), 89% of the total change.
Gross margin was 11.1%, up 1.6 points from a year earlier. Operating profit was $739K, a 5.3% margin (up 2.6 points year over year). Of the extra revenue versus a year earlier, 48% reached operating profit, above the 3% margin then. Operating expenses fell 9% while revenue rose 6%. Net earnings were $611K, up 114% year over year. The effective tax rate was 21.5%.
Operating cash flow was $616K (down 63% year over year), 101% of net earnings. Non-cash charges added back $79K of depreciation and amortization and $45K of share-based compensation. Working capital and other items used $119K. Capital expenditures of $116K left free cash flow of $500K.
Questions
What was Integrated Biopharma's revenue in the third quarter fiscal 2025?
Integrated Biopharma (INBP) reported revenue of $13.9M for the third quarter fiscal 2025 (Q3 FY25), +6% from a year earlier and +11% from the quarter before.
Was Integrated Biopharma profitable in the third quarter fiscal 2025?
Operating profit was $739K (5.3% of revenue) and net earnings $611K.